Find information on Industry Analysis Report

Posts tagged ‘Diagnostics’

Zimmer Medical Device Company Intelligence Report

Headquartered in Warsaw, Indiana, US, Zimmer develops, manufactures and markets orthopaedic reconstructive implants (including knee, hip and extremities), spinal and trauma devices, biologics, dental implants, and related surgical products, which include surgical supplies and instruments designed to aid in surgical procedures and post-operation rehabilitation.

Zimmer is a leading supplier in the orthopaedics industry, a position which was confirmed through its October 2003 acquisition of Centerpulse AG. Centerpulse provided Zimmer with the leading position in the European reconstructive market and entry into the spine market, one of the fastest-growth segments in orthopaedics. The company’s spinal business has been expanded further with the acquisitions of Endius in April 2007 and Abbot Spine in October 2008.

Another key acquisition – in April 2004 – that has led to strong growth for Zimmer, was that of its alliance partner, Implex, the developer of Hedrocel biomaterial, which Zimmer has marketed as Trabecular Metal Technology since 2000.

More recent acquisitions have expanded Zimmer’s surgical products portfolio. These include Sodem Diffusion SA, the manufacturer of SoPlus Orthopaedic Surgical Power Tools; and Synvasive Technology, producer of Stablecut surgical saw blades and the eLibra Dynamic Knee Balancing System for soft tissue balancing.

Zimmer manages its operations through three geographic segments – the Americas (consisting principally of the US and includes other North, Central and South American markets), Europe (consisting principally of Europe and includes the Middle East and Africa) and Asia Pacific (consisting principally of Japan and Australia and includes other Asian and Pacific markets).

Zimmer has operations in more than 25 countries and sells products in over 100. In 2011, the company generated a net profit of US$760.0 million on sales of US$4,451.8 million. It employs approximately 8,700 people worldwide.

This company report provides
Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches

Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded

Mergers, Acquisitions, Minority Investments, Joint Ventures and Divestments

Litigation

Key Corporate Events

For more information kindly visit :
Zimmer Medical Device Company Intelligence Report

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://bharatbook.posterous.com/
http://healthcareraj.blogspot.com/

Advertisements

Sorin Medical Device Company Intelligence Report

Sorin develops and manufactures medical technologies and therapies for cardiac surgery and for the treatment of cardiac rhythm disorders. At the end of 2008, the company completed a programme of strategic divestitures and concluded a plan to restructure its business portfolio. The divestitures included the sale of its endovascular, coronary stent and renal care businesses. This has allowed the company to better focus on its three core businesses – Cardiac Rhythm Management (CRM), Cardiopulmonary and Heart Valves.

* The CRM business produces pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronisation therapy defibrillators (CRT-Ds), programmers, electrodes, electrophysiology leads and holter monitors.
* The Cardiopulmonary business produces extracorporeal blood circulation systems including oxygenators, heart-lung machines, perfusion tubing sets, autotransfusion systems and disposables, cannulae and endoscopic vessel harvesting (EVH) systems.
* The Heart Valves business offers mechanical heart valves, tissue heart valves, sutureless self-anchoring tissue valves and annuloplasty rings. Sorin is also a distributor of endovascular devices.

Sorin’s recent investments in developing its business include the purchase of equity stakes in Enopace Biomedical (a company developing a neuromodulation system to treat patients with congestive heart failure) and MD Start (a venture capital incubator), as well as the acquisition of a line of arterial and venous cannulae from Endoscopic Technologies Inc and the purchase of Gish Biomedical (a producer of disposable medical devices for cardiovascular surgery).

Sorin’s principal manufacturing and R&D facilities are located in Italy, France, Germany, Canada and the US. The company is present in more than 80 countries throughout the world and serves over 5,000 public and private health institutions.

The Sorin Group was created through the demerger of Snia’s biomedical operations. It was listed separately on the Online Stock Market of the Milan Securities Exchange in January 2004. As of January 2012, its main shareholders included: Bios SpA (19.1%); Tower 6Bis Sarl (6.7%); Banca Monte Dei Paschi di Siena SpA (7.3%); Unipol Assicurazioni SpA (4.6%); GE Capital Equity Holdings (6.4%); and Norges Bank (2.0%).

In 2011, Sorin generated net income of EUR58 million on sales of EUR743 million. The company employs more than 3,740 people worldwide.

This company report provides
Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches

Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded

Mergers, Acquisitions, Minority Investments, Joint Ventures and Divestments

Litigation

Key Corporate Events

For more information kindly visit :
Sorin Medical Device Company Intelligence Report

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://bharatbook.posterous.com/
http://healthcareraj.blogspot.com/

Roche Diagnostics Medical Device Company Intelligence Report

Headquartered in Basel, Switzerland, Roche Diagnostics is a division of F. Hoffmann-La Roche Ltd (Roche), the world’s largest biotech company with combined strengths in pharmaceuticals and diagnostics.

Roche Diagnostics is a leading player in in vitro diagnostics (IVD) – tests performed in a laboratory or at the point-of-care (PoC) on blood and other samples from patients – with a 20% share of the global market. It is also a leader in diabetes management.

This profile focuses on Roche Diagnostics’ PoC activities (part of its Professional Diagnostics business), which produces coagulation monitoring systems, professional blood glucose testing and monitoring systems, cardiac marker testing devices, blood gas/electrolyte testing and urinalysis screening products, and its Diabetes Care business, which produces blood glucose monitoring and insulin delivery systems that are used in hospitals, doctors’ offices or patients’ homes for self-testing.

The principal activities of the Professional Diagnostics PoC and Diabetes Care businesses are located in Switzerland, the US, Germany and Austria.
In January 2012, Roche began focusing on expanding its coagulation testing product line in North America beyond physicians’ offices and out-patient clinics, with the development of a full line of coagulation analysers for hospitals and reference labs. To achieve this, the company acquired Verum Diagnostica, a Munich, Germany-based company focused on platelet function testing, which is claimed to be the fastest-growing field in the coagulation diagnostics market. The coagulation analyser product line is expected to be introduced in the US and Canada in 2014, subject to regulatory approval and other requirements. Further attempts to expand into North America were made in 2012 with the failed attempt to acquire Illumina Inc, a San Diego, California-based developer of life-science tools and integrated systems for the analysis of genetic variation and function (see Strategic Focus section). Roche believed this acquisition would have secured its position in the sequencing and microarrays market in North America.

In 2011, Roche Diagnostics was responsible for 22.9% of the Roche Group’s revenue.

This company report provides
Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches
Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded

Mergers, Acquisitions, and Divestments

Key Corporate Events
OVERVIEW1
FINANCIAL REVIEW3
First Quarter 2012 Financial Results 3
2011 Financial Results 3
Professional Diagnostics6
Diabetes Care7
Molecular Diagnostics7
Applied Science7
Tissue Diagnostics8
Five-Year Financial Data 9
Outlook 10
Employees 10
STRATEGIC FOCUS11
Operational Excellence Programme11
R&D Strategy 12
PRODUCTS13
Recent Key Events 14
Coagulation Monitoring Systems17
Clinical Chemistry/Immunology Testing Solutions17

For more information kindly visit :
Roche Diagnostics Medical Device Company Intelligence Report

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://bharatbook.posterous.com/
http://healthcareraj.blogspot.com/

Market Growth Outlook in the Power Industry – 2012-2013

Synopsis

• Analysis of opinions drawn from leading power industry executives.
• Analysis of market growth practices.
• Analysis of the demand in emerging markets and growth expectations in developed countries.

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading power industry executives. It analyzes how demand and growth expectations are set to change in the power industry in 2012–13. The report also provides access to information categorized by company type, company turnover, buyer, supplier and region.

Scope

• The opinions and forward looking statements of 330 industry executives have been captured in our in-depth survey, of which 29% represent Director and C-level respondents.
• The research is based on primary survey research conducted by ICD Research accessing its B2B panels comprised of senior purchase decision makers and leading supplier organizations.
• The geographical scope of the research is global – drawing on the activity and expectations of leading industry players across the Americas, Europe, Asia-Pacific, Africa and Middle East.
• This report covers data and analysis on demand in emerging markets and growth expectations in developed countries.

Find More:

Market Growth Outlook in the Power Industry – 2012-2013

Indian Diagnostic Services Market

Indian Diagnostic Services Market Outlook 2015

In the Indian healthcare services industry, a largely unorganized diagnostic services is one of the fastest growing segments. Several important developments and factors have created a market that has witnessed an active participation of domestic players, and attracted foreign companies. As per the estimations, carried out in our latest research report, the Indian diagnostic services market will grow at the compound annual rate of around 26% during 2012-2015 on back of huge investments, fast expansion into tier II & III cities, and strong government support strengthening the healthcare infrastructure in the country.

Diagnostic Services MarketAccording to our comprehensive study, “Indian Diagnostic Services Market Outlook 2015”, the market’s future landscape will be defined by major advancements in the IT, and sophisticated lab testing mechanism. Currently, there exists a tremendous growth opportunity for the market players in tier II and III cities, wherein the educated middle class population is becoming more sophisticated with respect to preventive healthcare check-ups. In order to help clients understand the cost of several common pathological and radiological tests in these cities, we have provided an in-depth analysis of the cost assessment in a comparative manner. For getting this root-level information and analysis, we conducted extensive primary research, and market surveys.

By studying the industry’s performance in urban and rural areas, we found out why the quality of diagnostics services differs in urban India, and how much share organized and unorganized players hold in the rural market. We observed that some of the best business models exist in the Indian diagnostic services market. With a view to understanding this, our report has analyzed the most common models, such as PPP, hub and spoke model and single specialty model. Our broad research work includes consumer behavior analysis, industry trends, and presents forecasts for the market and its segments. The report also provides an overview of the competitive landscape, and regulatory environment that will prove decisive for the clients.

Find More:

Indian Diagnostic Services Market

Related Reports:

Tag Cloud